Why the study?
Osimertinib cardiotoxicity raises critical concerns, but its incidence, risk factors, and management remain poorly understood and require further mechanistic exploration.
Does osimertinib induce cardiotoxicity via MPO and the AMPK/PI3K/AKT/eNOS pathway?
Does osimertinib induce cardiotoxicity via MPO and the AMPK/PI3K/AKT/eNOS pathway?
Osimertinib induces cardiotoxicity through MPO upregulation and inhibition of the AMPK/PI3K/AKT/eNOS pathway, suggesting MPO as a potential biomarker or therapeutic target for safety management.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to monitor cardiac function on osimertinib; animal data leaves open human mechanistic confirmation.
Introduction Osimertinib, a third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI), is central to first-line therapy for EGFR-mutant Non-Small Cell Lung Cancer (NSCLC), showing improved outcomes; however, its cardiotoxicity raises critical concerns. The incidence, risk factors, and management of this condition remain poorly understood and require further mechanistic exploration. This study aimed to investigate the risk signals, mechanisms, and causal associations of osimertinib-induced cardiotoxicity using multilevel analyses, focusing on myeloperoxidase (MPO) and the AMPK/PI3K/AKT/eNOS pathway. Methods The study methods included: (1) disproportionality analyses of FAERS and VigiBase (Q1 2016-Q4 2024), (2) network pharmacology for targets/pathways, (3) Mendelian randomization for causal validation, and (4) animal experiments to test the mechanisms. The exposures were osimertinib in real-world data; in animals, the exposures were osimertinib (8.33 mg/kg, i. p.) alone or with inhibitors (ABAH, Compound C, LY294002, L-NAME). The main outcomes and measures were (1) Real-world: CAE incidence/spectrum/risk signals (ROR, PRR, IC; e.g., heart failure, arrhythmias) (2) Molecular: Core targets/pathways (e.g., PI3K/AKT). via network pharmacology and genetically validated targets via Mendelian randomization. (3) In vivo : Cardiac function (LVEF, LVFS), ECG (QT), myocardial damage, apoptosis, oxidative stress (MDA, SOD), and inflammation (IL-1β, IL-6, TNF-α). Results Disproportionality analyses showed high signals for cardiac dysfunction (ROR = 16.10, FAERS), cardiotoxicity (ROR = 8.43, FAERS), and long QT syndrome (ROR = 15.85, VigiBase). Network pharmacology identified 111 overlapping targets with core targets in the PI3K/AKT pathway. Mendelian randomization validated nine targets related to PI3K/AKT with causal ties to arrhythmias/heart failure. In animal experiments, osimertinib upregulated MPO, inhibited AMPK/PI3K/AKT/eNOS, and induced cardiac dysfunction, damage, apoptosis, oxidative stress, and inflammation. MPO inhibition attenuated these effects, and co-administration with pathway inhibitors reversed the protective effect. Discussion Osimertinib induces cardiotoxicity via MPO upregulation, which inhibits the AMPK/PI3K/AKT/eNOS pathway. MPO and related pathways may serve as biomarkers or therapeutic targets, supporting risk monitoring and safety management in osimertinib use.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: